{"product_id":"diagnostic-pathology-molecular-oncology-hardback-9780323611442","title":"Diagnostic Pathology: Molecular Oncology (Hardback) 9780323611442","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eDiagnostic Pathology: Molecular Oncology\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cp\u003eA practical, clinical approach to the latest in molecular oncology\u003c\/p\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eMohammad A. Vasef (Author), Aaron Auerbach (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780323611442, Elsevier Health Sciences\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 8 October 2019\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e1016 pages, \u003cp\u003eApprox. 2700 full-color illustrations\u003c\/p\u003e\n\u003cbr\u003e28.1 x 22.2 x 4.8 cm, 3.08 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eCovering all aspects of molecular pathology as it relates to the transformation and pathogenesis of cancer, this award-winning volume in the \u003ci\u003eDiagnostic Pathology\u003c\/i\u003e series is an\u003cb\u003e expert resource for pathologists at all levels of experience and training\u003c\/b\u003e, both as a quick reference and as an efficient review to improve knowledge and skills. This \u003cb\u003eeasily accessible, point-of-care reference\u003c\/b\u003e features templated, bulleted content that is generously illustrated with charts, graphs, tables, and color photomicrographs of histology with special stains. It offers a \u003cb\u003epractical, clinical approach\u003c\/b\u003e to examining how molecular mutations affect common medical diseases and \u003cb\u003eidentifies the relevant and appropriate molecular tests\u003c\/b\u003e to perform for a complete work-up in the era of molecular-targeted therapies.\u003c\/p\u003e\n\u003cul\u003e \u003cli\u003eProvides \u003cb\u003eupdated information\u003c\/b\u003e on molecular mutations in different tumors, including solid tumors and hematopoietic neoplasms, and \u003cb\u003enew targeted therapies\u003c\/b\u003e geared toward these molecular alterations\u003c\/li\u003e  \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eDiscusses now widely used \u003cb\u003eimmunotherapy treatments,\u003c\/b\u003e including how immunotherapy has revolutionized the treatment of many neoplasms such as breast and lung carcinomas and lymphoma\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eFeatures \u003cb\u003emore than 2,000 annotated images throughout\u003c\/b\u003e, including H\u0026amp;E stains, immunostains, and FISH images\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eCovers timely topics such as:\u003c\/li\u003e \u003cul\u003e  \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eRecent advances in \u003cb\u003ecancer immunotherapy\u003c\/b\u003e, specifically in the molecular basis of immunotherapy\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eNewly discovered \u003cb\u003etargeted therapies\u003c\/b\u003e, including multiple lung carcinoma therapies now considered for patients based on existing mutations to specific genes (KRAS, ALK, BRAF, and ROS)\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eThe need for integration of \u003cb\u003emyeloid and lymphoid gene panels\u003c\/b\u003e due to increased knowledge from next generation sequencing studies of new mutations and the resulting newly developed molecular targets\u003c\/li\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eIncreased usage of \u003cb\u003enext generation sequencing techniques\u003c\/b\u003e\n\u003c\/li\u003e   \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eChanges to \u003cb\u003ehematopoietic tumor details\u003c\/b\u003e based on revised WHO guidelines\u003c\/li\u003e \u003c\/ul\u003e  \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eRecipient of a 2016 BMA Award: \u003cb\u003eHighly Commended, Pathology\u003c\/b\u003e (previous edition)\u003c\/li\u003e \u003cb\u003e  \u003c\/b\u003e\u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eEnhanced eBook version included with purchase, which allows you to access all of the text, figures, and references from the book on a variety of devices\u003c\/li\u003e \u003c\/ul\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eDP2 Molecular Oncology: Auerbach and Vasef\u003c\/p\u003e \u003cp\u003eIntroduction \u003c\/p\u003e \u003cp\u003eStructure of Chromosomes and Nucleic Acids \u003c\/p\u003e \u003cp\u003eDNA Replication, Transcription, and Translation \u003c\/p\u003e \u003cp\u003eGene Mutations \u003c\/p\u003e \u003cp\u003eCommon Techniques for Analysis of Alterations in Chromosomes and DNA \u003c\/p\u003e \u003cp\u003eCytogenetics and FISH \u003c\/p\u003e \u003cp\u003eChromosomal Microarray \u003c\/p\u003e \u003cp\u003eAmplification Methods \u003c\/p\u003e \u003cp\u003eDNA High-Resolution Melting Curve Analysis \u003c\/p\u003e \u003cp\u003eSequencing Technologies \u003c\/p\u003e \u003cp\u003eHigh-Throughput Methods in Molecular Pathology \u003c\/p\u003e \u003cp\u003eDNA Methylation Analysis \u003c\/p\u003e \u003cp\u003eMolecular Genetic Tests in Hematopoietic Tumors \u003c\/p\u003e \u003cp\u003e*BCR-ABL1* Fusion Gene \u003c\/p\u003e \u003cp\u003e*PDGFRA*, *PDGFRB*, and *FGFR1* Rearrangements Detection \u003c\/p\u003e \u003cp\u003ePML-RARA Fusion Gene \u003c\/p\u003e \u003cp\u003eReverse Transcription PCR for Other Myeloid Leukemia Transcripts \u003c\/p\u003e \u003cp\u003eFLT3, NPM1, and CEBPA Mutations \u003c\/p\u003e \u003cp\u003eJAK2 Mutations and Rearrangements \u003c\/p\u003e \u003cp\u003eMPL Mutations \u003c\/p\u003e \u003cp\u003eCalreticulin (CALR) Mutations \u003c\/p\u003e \u003cp\u003eCSF3R Mutations \u003c\/p\u003e \u003cp\u003eSETBP1 Mutations \u003c\/p\u003e \u003cp\u003eKIT Mutations \u003c\/p\u003e \u003cp\u003eIDH1 and IDH2 Mutations \u003c\/p\u003e \u003cp\u003eOther Mutations and Gene Panel Testing in Myeloid Neoplasms \u003c\/p\u003e \u003cp\u003eImmunoglobulin Heavy (IGH) Chain Gene Rearrangements \u003c\/p\u003e \u003cp\u003eT-Cell Receptor Gamma (TRG) and Delta (TRD) Chain Rearrangements \u003c\/p\u003e \u003cp\u003eT-Cell Receptor Beta (TRB) Chain Gene Rearrangements \u003c\/p\u003e \u003cp\u003eSouthern Blot Analysis of Antigen Receptor Genes \u003c\/p\u003e \u003cp\u003eEBV-Associated Human Neoplasms \u003c\/p\u003e \u003cp\u003eMYD88 Mutation \u003c\/p\u003e \u003cp\u003eNOTCH1 Mutation \u003c\/p\u003e \u003cp\u003eEZH2 Mutation \u003c\/p\u003e \u003cp\u003eMolecular Genetic Tests in Solid Tumors, Bone and Soft Tissue Tumors, and CNS Tumors \u003c\/p\u003e \u003cp\u003eALK Gene Rearrangements and Mutations \u003c\/p\u003e \u003cp\u003eFISH for ROS1 Rearrangements \u003c\/p\u003e \u003cp\u003eRET Rearrangements \u003c\/p\u003e \u003cp\u003eFISH for MET Amplifications \u003c\/p\u003e \u003cp\u003eFISH for ERBB2 (HER2) Gene Amplifications \u003c\/p\u003e \u003cp\u003eKRAS Mutations \u003c\/p\u003e \u003cp\u003eBRAF Mutations \u003c\/p\u003e \u003cp\u003eEGFR Mutations \u003c\/p\u003e \u003cp\u003eTargeted Hotspot Gene Panel Using Massively Parallel Sequencing (Next Generation Sequencing) \u003c\/p\u003e \u003cp\u003eTargeted Hotspot Gene Panel Table \u003c\/p\u003e \u003cp\u003eMGMT Promoter Gene Methylation Assay \u003c\/p\u003e \u003cp\u003eMET Exon 14 Skip Mutations \u003c\/p\u003e \u003cp\u003eNGS Panels for NCI MATCH \u003c\/p\u003e \u003cp\u003eFISH for 1p\/19q Deletions \u003c\/p\u003e \u003cp\u003eIDH1 and IDH2 Mutations \u003c\/p\u003e \u003cp\u003eMolecular Basis of Immunotherapy in Cancer \u003c\/p\u003e \u003cp\u003eMolecular Pathology of Myeloid Neoplasms \u003c\/p\u003e \u003cp\u003eMolecular Pathology of Myeloid Neoplasms \u003c\/p\u003e \u003cp\u003eMolecular Work-Up of Myeloid Neoplasms \u003c\/p\u003e \u003cp\u003eMyeloproliferative Neoplasms \u003c\/p\u003e \u003cp\u003eChronic Myeloid Leukemia, BCR-ABL1 Positive \u003c\/p\u003e \u003cp\u003eChronic Neutrophilic Leukemia \u003c\/p\u003e \u003cp\u003ePolycythemia Vera \u003c\/p\u003e \u003cp\u003ePrimary Myelofibrosis \u003c\/p\u003e \u003cp\u003eEssential Thrombocythemia \u003c\/p\u003e \u003cp\u003eChronic Eosinophilic Leukemia, NOS \u003c\/p\u003e \u003cp\u003eMastocytosis \u003c\/p\u003e \u003cp\u003eMyeloproliferative Neoplasms, Unclassifiable \u003c\/p\u003e \u003cp\u003eMastocytosis \u003c\/p\u003e \u003cp\u003eMyeloid\/Lymphoid Neoplasms With PDGFRA Rearrangement \u003c\/p\u003e \u003cp\u003eMyeloid\/Lymphoid Neoplasms With PDGFRB Rearrangement \u003c\/p\u003e \u003cp\u003eMyeloid\/Lymphoid Neoplasms With FGFR1 Rearrangement \u003c\/p\u003e \u003cp\u003eMyeloid\/Lymphoid Neoplasms With PCM1-JAK2 \u003c\/p\u003e \u003cp\u003eMyelodysplastic Syndrome (MDS) \u003c\/p\u003e \u003cp\u003eOverview and Classification of MDS \u003c\/p\u003e \u003cp\u003eMyelodysplastic Syndromes With Single Lineage Dysplasia \u003c\/p\u003e \u003cp\u003eMyelodysplastic Syndrome With Ring Sideroblasts \u003c\/p\u003e \u003cp\u003eMyelodysplastic Syndrome With Multilineage Dysplasia \u003c\/p\u003e \u003cp\u003eMyelodysplastic Syndrome With Excess Blasts \u003c\/p\u003e \u003cp\u003eMyelodysplastic Syndrome With Excess Blasts and Erythroid Predominance\u003c\/p\u003e \u003cp\u003eMyelodysplastic Syndrome With Excess Blasts and Fibrosis\u003c\/p\u003e \u003cp\u003eMyelodysplastic Syndrome With Isolated del(5q) \u003c\/p\u003e \u003cp\u003eMyelodysplastic Syndrome, Unclassifiable \u003c\/p\u003e \u003cp\u003eChildhood Myelodysplastic Syndrome and Refractory Cytopenia of Childhood \u003c\/p\u003e \u003cp\u003eMyelodysplastic\/Myeloproliferative Neoplasms \u003c\/p\u003e \u003cp\u003eOverview of Myelodysplastic\/Myeloproliferative Neoplasms \u003c\/p\u003e \u003cp\u003eChronic Myelomonocytic Leukemia \u003c\/p\u003e \u003cp\u003eAtypical Chronic Myeloid Leukemia, BCR-ABL1 Negative \u003c\/p\u003e \u003cp\u003eJuvenile Myelomonocytic Leukemia \u003c\/p\u003e \u003cp\u003eMyelodysplastic\/Meloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis \u003c\/p\u003e \u003cp\u003eMyelodysplastic\/Myeloproliferative Neoplasm, Unclassifiable \u003c\/p\u003e \u003cp\u003eMyeloid Neoplasms With Germline Predisposition \u003c\/p\u003e \u003cp\u003eAcute Myeloid Leukemia \u003c\/p\u003e \u003cp\u003eOverview of Acute Myeloid Leukemia \u003c\/p\u003e \u003cp\u003eAcute Myeloid Leukemia With t(8;21); RUNX1-RUNX1T1 \u003c\/p\u003e \u003cp\u003eAcute Myeloid Leukemia With inv(16) or t(16;16); CBFB-MYH11 \u003c\/p\u003e \u003cp\u003eAcute Promyelocytic Leukemia With t(15;17); PML-RARA \u003c\/p\u003e \u003cp\u003eAcute Myeloid Leukemia With t(9;11); MLLT3-KMT2A \u003c\/p\u003e \u003cp\u003eAcute Myeloid Leukemia With t(6:9); DEK-NUP214 \u003c\/p\u003e \u003cp\u003eAcute Myeloid Leukemia With inv(3) or t(3;3); RPN1-MECOM \u003c\/p\u003e \u003cp\u003eAcute Myeloid Leukemia (Megakaryoblastic) With t(1;22); RBM15-MKL1 \u003c\/p\u003e \u003cp\u003eAcute Myeloid Leukemia With BCR-ABL1 \u003c\/p\u003e \u003cp\u003eAcute Myeloid Leukemia With Gene Mutations \u003c\/p\u003e \u003cp\u003eAcute Myeloid Leukemia With Mutated NPM1\u003c\/p\u003e \u003cp\u003eAcute Myeloid Leukemia With Biallelic Mutation of CEBPA\u003c\/p\u003e \u003cp\u003eAcute Myeloid Leukemia With Mutated RUNX1\u003c\/p\u003e \u003cp\u003eAcute Myeloid Leukemia With Myelodysplasia-Related Changes \u003c\/p\u003e \u003cp\u003eAcute Myeloid Leukemia, NOS \u003c\/p\u003e \u003cp\u003eTherapy-Related Myeloid Neoplasms \u003c\/p\u003e \u003cp\u003eMyeloid Sarcoma \u003c\/p\u003e \u003cp\u003eMyeloid Proliferations Associated With Down Syndrome \u003c\/p\u003e \u003cp\u003eBlastic Plasmacytoid Dendritic Cell Neoplasm \u003c\/p\u003e \u003cp\u003eBlastic Plasmacytoid Dendritic Cell Neoplasm \u003c\/p\u003e \u003cp\u003eAcute Leukemias of Ambiguous Lineage \u003c\/p\u003e \u003cp\u003eOverview of Ambiguous Lineage Leukemias \u003c\/p\u003e \u003cp\u003eAcute Undifferentiated and Mixed Phenotype Acute Leukemias \u003c\/p\u003e \u003cp\u003eMolecular Pathology of Lymphoid Neoplasms \u003c\/p\u003e \u003cp\u003eOverview of Lymphoid Neoplasms \u003c\/p\u003e \u003cp\u003eMolecular Work-Up of Lymphoid Neoplasms \u003c\/p\u003e \u003cp\u003ePrecursor Lymphoid Neoplasms \u003c\/p\u003e \u003cp\u003eB-Lymphoblastic Leukemia\/Lymphoma, Not Otherwise Specified \u003c\/p\u003e \u003cp\u003eB-Lymphoblastic Leukemia\/Lymphoma With Recurrent Genetic Abnormalities \u003c\/p\u003e \u003cp\u003eB-Lymphoblastic Leukemia\/Lymphoma, BCR-ABL1-Like \u003c\/p\u003e \u003cp\u003eT-Lymphoblastic Leukemia\/Lymphoma \u003c\/p\u003e \u003cp\u003eMature B-Cell Neoplasms \u003c\/p\u003e \u003cp\u003eSmall Lymphocytic Lymphoma\/Chronic Lymphocytic Leukemia \u003c\/p\u003e \u003cp\u003eMonoclonal B-Cell Lymphocytosis \u003c\/p\u003e \u003cp\u003eB-Cell Prolymphocytic Leukemia \u003c\/p\u003e \u003cp\u003eSplenic Marginal Zone Lymphoma \u003c\/p\u003e \u003cp\u003eHairy Cell Leukemia \u003c\/p\u003e \u003cp\u003eSplenic B-Cell Lymphoma\/Leukemia, Unclassifiable \u003c\/p\u003e \u003cp\u003eLymphoplasmacytic Lymphoma \u003c\/p\u003e \u003cp\u003eIgM Monoclonal Gammopathy of Undetermined Significance \u003c\/p\u003e \u003cp\u003eHeavy Chain Disease \u003c\/p\u003e \u003cp\u003eµ-Heavy Chain Disease\u003c\/p\u003e \u003cp\u003e?-Heavy Chain Disease\u003c\/p\u003e \u003cp\u003ea-Heavy Chain Disease\u003c\/p\u003e \u003cp\u003ePlasma Cell Myeloma \u003c\/p\u003e \u003cp\u003eMarginal Zone Lymphoma \u003c\/p\u003e \u003cp\u003eFollicular Lymphoma \u003c\/p\u003e \u003cp\u003eLarge B-Cell Lymphoma With IRF4 Rearrangement \u003c\/p\u003e \u003cp\u003eMantle Cell Lymphoma \u003c\/p\u003e \u003cp\u003eDiffuse Large B-Cell Lymphoma \u003c\/p\u003e \u003cp\u003eT-Cell\/Histiocyte-Rich Large B-Cell Lymphoma \u003c\/p\u003e \u003cp\u003eDiffuse Large B-Cell Lymphoma Associated With Chronic Inflammation \u003c\/p\u003e \u003cp\u003eBurkitt Lymphoma \u003c\/p\u003e \u003cp\u003eHigh-Grade B-Cell Lymphoma \u003c\/p\u003e \u003cp\u003eMature T- and NK-Cell Neoplasms \u003c\/p\u003e \u003cp\u003eT-Cell Prolymphocytic Leukemia \u003c\/p\u003e \u003cp\u003eChronic Lymphoproliferative Disorder of NK Cells \u003c\/p\u003e \u003cp\u003eAggressive NK-Cell Leukemia \u003c\/p\u003e \u003cp\u003eExtranodal NK-\/T-Cell Lymphoma, Nasal Type \u003c\/p\u003e \u003cp\u003eAdult T-Cell Leukemia\/Lymphoma \u003c\/p\u003e \u003cp\u003eIntestinal T-Cell Lymphoma \u003c\/p\u003e \u003cp\u003eHepatosplenic T-Cell Lymphoma \u003c\/p\u003e \u003cp\u003eSubcutaneous Panniculitis-Like T-Cell Lymphoma \u003c\/p\u003e \u003cp\u003eMycosis Fungoides\/Sezary Syndrome \u003c\/p\u003e \u003cp\u003ePrimary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders \u003c\/p\u003e \u003cp\u003ePrimary Cutaneous Peripheral T-Cell Lymphoma, Rare Subtypes \u003c\/p\u003e \u003cp\u003ePeripheral T-Cell Lymphoma, Not Otherwise Specified \u003c\/p\u003e \u003cp\u003eAngioimmunoblastic T-Cell Lymphoma \u003c\/p\u003e \u003cp\u003eAnaplastic Large Cell Lymphoma, ALK-Negative \u003c\/p\u003e \u003cp\u003eAnaplastic Large Cell Lymphoma, ALK-Positive \u003c\/p\u003e \u003cp\u003eBreast Implant-Associated Anaplastic Large Cell Lymphoma \u003c\/p\u003e \u003cp\u003eDetermination of Clonality in B-, T-, and NK-Cell Neoplasms \u003c\/p\u003e \u003cp\u003eLymphoma-Associated Chromosomal Translocations \u003c\/p\u003e \u003cp\u003eMolecular Pathology of Dendritic Cell and Histiocytic Neoplasms \u003c\/p\u003e \u003cp\u003eHistiocytic Sarcoma \u003c\/p\u003e \u003cp\u003eTumors Derived From Langerhans Cells \u003c\/p\u003e \u003cp\u003eInterdigitating Dendritic Cell Tumor \u003c\/p\u003e \u003cp\u003eInterdigitating Dendritic Cell Sarcoma \u003c\/p\u003e \u003cp\u003eFollicular Dendritic Cell Neoplasm \u003c\/p\u003e \u003cp\u003eFibroblastic Reticular Cell Tumor \u003c\/p\u003e \u003cp\u003eDisseminated Juvenile Xanthogranuloma \u003c\/p\u003e \u003cp\u003eErdheim-Chester Disease \u003c\/p\u003e \u003cp\u003eMolecular Pathology of Solid Tumors \u003c\/p\u003e \u003cp\u003eHead and Neck, Including Sinonasal Tumors and Salivary Glands \u003c\/p\u003e \u003cp\u003eHPV-Related Squamous Cell Carcinoma \u003c\/p\u003e \u003cp\u003eHead and Neck Mucosal Squamous Cell Carcinoma, Non-HPV-Related \u003c\/p\u003e \u003cp\u003eImportant Alterations in Non-HPV-Related Head \u0026amp; Neck SCC \u003c\/p\u003e \u003cp\u003eTranslocation-Specific Salivary Gland Tumors \u003c\/p\u003e \u003cp\u003eNasopharyngeal EBV-Related Squamous Carcinoma \u003c\/p\u003e \u003cp\u003eOther Head and Neck Tumors \u003c\/p\u003e \u003cp\u003eThyroid \u003c\/p\u003e \u003cp\u003ePapillary Thyroid Carcinoma \u003c\/p\u003e \u003cp\u003eFollicular Thyroid Carcinoma \u003c\/p\u003e \u003cp\u003ePoorly Differentiated Thyroid Carcinoma \u003c\/p\u003e \u003cp\u003eUndifferentiated Thyroid Carcinoma \u003c\/p\u003e \u003cp\u003eMedullary Thyroid Carcinoma \u003c\/p\u003e \u003cp\u003eLung \u003c\/p\u003e \u003cp\u003eAdenocarcinoma, Lung \u003c\/p\u003e \u003cp\u003eSquamous Cell Carcinoma, Lung \u003c\/p\u003e \u003cp\u003eSmall Cell Neuroendocrine Carcinoma \u003c\/p\u003e \u003cp\u003eMesothelioma \u003c\/p\u003e \u003cp\u003eLuminal GI Tract \u003c\/p\u003e \u003cp\u003eGastric Adenocarcinoma \u003c\/p\u003e \u003cp\u003eColorectal Adenocarcinoma and Precancerous Lesions \u003c\/p\u003e \u003cp\u003eGastrointestinal Stromal Tumor \u003c\/p\u003e \u003cp\u003eLiver \u003c\/p\u003e \u003cp\u003eHNF1a-Inactivated Hepatocellular Adenoma \u003c\/p\u003e \u003cp\u003eß-Catenin-Activated Hepatocellular Adenoma \u003c\/p\u003e \u003cp\u003eInflammatory Hepatocellular Adenoma \u003c\/p\u003e \u003cp\u003eHepatocellular Carcinoma \u003c\/p\u003e \u003cp\u003ePancreaticobiliary \u003c\/p\u003e \u003cp\u003ePancreatic Ductal Adenocarcinoma \u003c\/p\u003e \u003cp\u003ePancreatic Mucinous Cystic Neoplasm \u003c\/p\u003e \u003cp\u003ePancreatic Intraductal Papillary Mucinous Neoplasm \u003c\/p\u003e \u003cp\u003eCholangiocarcinoma \u003c\/p\u003e \u003cp\u003eTestis \u003c\/p\u003e \u003cp\u003eTesticular Germ Cell Tumors \u003c\/p\u003e \u003cp\u003eKidney \u003c\/p\u003e \u003cp\u003eClear Cell Renal Cell Carcinoma \u003c\/p\u003e \u003cp\u003eChromophobe Renal Cell Carcinoma \u003c\/p\u003e \u003cp\u003ePapillary Renal Cell Carcinoma \u003c\/p\u003e \u003cp\u003eMiT Family Translocation Renal Cell Carcinoma \u003c\/p\u003e \u003cp\u003eWilms Tumor \u003c\/p\u003e \u003cp\u003eClear Cell Sarcoma of Kidney \u003c\/p\u003e \u003cp\u003eOncocytoma \u003c\/p\u003e \u003cp\u003eRhabdoid Tumor of Kidney \u003c\/p\u003e \u003cp\u003eBladder \u003c\/p\u003e \u003cp\u003eUrothelial Carcinoma \u003c\/p\u003e \u003cp\u003eAdrenal \u003c\/p\u003e \u003cp\u003ePheochromocytoma\/Paraganglioma \u003c\/p\u003e \u003cp\u003eAdrenal Cortical Carcinoma \u003c\/p\u003e \u003cp\u003eNeuroblastoma \u003c\/p\u003e \u003cp\u003eAdrenal Cortical Adenoma \u003c\/p\u003e \u003cp\u003eProstate \u003c\/p\u003e \u003cp\u003eProstatic Adenocarcinoma, Acinar Type and High-Grade Prostatic Intraepithelial Neoplasia \u003c\/p\u003e \u003cp\u003eBreast \u003c\/p\u003e \u003cp\u003eADH and DCIS (Dysplastic, Premalignant) \u003c\/p\u003e \u003cp\u003eDuctal Carcinomas \u003c\/p\u003e \u003cp\u003eLobular Carcinoma \u003c\/p\u003e \u003cp\u003eCarcinoma With Medullary Features, Breast \u003c\/p\u003e \u003cp\u003eMetaplastic Breast Carcinoma \u003c\/p\u003e \u003cp\u003ePhyllodes Tumors \u003c\/p\u003e \u003cp\u003eBasal-Like and Triple-Negative Carcinomas \u003c\/p\u003e \u003cp\u003eCervix\/Vulva\/Vagina \u003c\/p\u003e \u003cp\u003ePreneoplastic Conditions, Cervix\/Vulva\/Vagina \u003c\/p\u003e \u003cp\u003eSquamous Cell Carcinoma, Cervix\/Vulva\/Vagina \u003c\/p\u003e \u003cp\u003eAdenocarcinoma, Cervix\/Vulva\/Vagina \u003c\/p\u003e \u003cp\u003eUterus \u003c\/p\u003e \u003cp\u003eEndometrial Intraepithelial Neoplasia \u003c\/p\u003e \u003cp\u003eUterine Endometrioid Carcinoma \u003c\/p\u003e \u003cp\u003eUterine Serous Carcinoma \u003c\/p\u003e \u003cp\u003eClear Cell Carcinoma, Uterus \u003c\/p\u003e \u003cp\u003eUterine Sarcomas \u003c\/p\u003e \u003cp\u003eOvaries\/Fallopian Tube \u003c\/p\u003e \u003cp\u003eSerous Tumors of Ovary and Fallopian Tube \u003c\/p\u003e \u003cp\u003eOther Surface Epithelial Tumors of the Ovary \u003c\/p\u003e \u003cp\u003eSex Cord-Stromal Tumors of the Ovary \u003c\/p\u003e \u003cp\u003eGerm Cell Tumor, Ovary \u003c\/p\u003e \u003cp\u003eSkin \u003c\/p\u003e \u003cp\u003ePreneoplastic Conditions, Skin \u003c\/p\u003e \u003cp\u003eMelanoma \u003c\/p\u003e \u003cp\u003eSquamous Cell Carcinoma, Skin \u003c\/p\u003e \u003cp\u003eBasal Cell Carcinoma, Skin \u003c\/p\u003e \u003cp\u003eOther Skin Conditions \u003c\/p\u003e \u003cp\u003eBone \u003c\/p\u003e \u003cp\u003eOsteosarcomas \u003c\/p\u003e \u003cp\u003eOverview of Molecular Pathology of Bone and Soft Tissue Tumors \u003c\/p\u003e \u003cp\u003eEwing Sarcoma \u003c\/p\u003e \u003cp\u003eOther Small Round Blue Cell Sarcomas \u003c\/p\u003e \u003cp\u003eGiant Cell Tumor of Bone \u003c\/p\u003e \u003cp\u003eIntermediate and Malignant Cartilaginous Tumors of Bone \u003c\/p\u003e \u003cp\u003eSoft Tissue \u003c\/p\u003e \u003cp\u003eOverview \u003c\/p\u003e \u003cp\u003eIntermediate and Malignant Myofibroblastic\/Fibroblastic Tumors\u003c\/p\u003e \u003cp\u003eLiposarcomas\u003c\/p\u003e \u003cp\u003eMuscle Sarcomas\u003c\/p\u003e \u003cp\u003eIntermediate and Malignant Vascular Tumors\u003c\/p\u003e \u003cp\u003eMalignant Peripheral Nerve Sheath Tumor\u003c\/p\u003e \u003cp\u003eRepresentative Genetic Findings in Bone and Soft Tissue Tumors\u003c\/p\u003e \u003cp\u003eSarcomas of Uncertain Differentiation \u003c\/p\u003e \u003cp\u003eRare Sarcomas of Uncertain Differentiation With Specific Molecular Alterations\u003c\/p\u003e \u003cp\u003eCNS \u003c\/p\u003e \u003cp\u003eHigh-Grade Astrocytoma \u003c\/p\u003e \u003cp\u003eLow-Grade Astrocytoma \u003c\/p\u003e \u003cp\u003ePilocytic Astrocytoma \u003c\/p\u003e \u003cp\u003eOligodendroglioma \u003c\/p\u003e \u003cp\u003eEpendymoma \u003c\/p\u003e \u003cp\u003eMedulloblastoma \u003c\/p\u003e \u003cp\u003eChoroid Plexus Tumors \u003c\/p\u003e \u003cp\u003eMeningioma \u003c\/p\u003e \u003cp\u003eRetinoblastoma \u003c\/p\u003e \u003cp\u003eQuality Assurance and Regulatory Issues \u003c\/p\u003e \u003cp\u003eFederal Agencies and Regulation of Laboratories \u003c\/p\u003e \u003cp\u003eFDA Regulations \u003c\/p\u003e \u003cp\u003eProficiency Testing and Accreditation\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Pathology [\u003ca title=\"See our other books on Pathology\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Pathology%20%5BMMF%5D%22\"\u003eMMF\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Elsevier","offers":[{"title":"Default Title","offer_id":46648522637592,"sku":"9780323611442","price":197.99,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/products\/9780323611442_527ac7ca-1e42-455e-ad3b-8424ba3863a9.jpg?v=1694990010","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/diagnostic-pathology-molecular-oncology-hardback-9780323611442","provider":"Freshly Printed Books","version":"1.0","type":"link"}